This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Otsuka Holdings Co., Ltd.
Drug Names(s): OPA-6566
Description: OPA-6566, an adenosine A2a receptor agonist, is being developed as an ophthalmic solution to reduce intraocular pressure in open-angle glaucoma or ocular hypertension patients. The compound has demonstrated the ability to lower intraocular pressure by stimulating aqueous humor outflow via trabecular meshwork by activation of the adenosine A2a receptor.
Deal Structure: OPA-6566 was discovered by Otsuka.
Otsuka and Acucela
Under the September 2010 agreement, Otsuka will contract Acucela to perform early clinical development of OPA-6566 in the United States and will grant Acucela an opt-in right to co-develop and co-promote the compound. In the event and after Acucela exercises the opt-in right, Otsuka and Acucela will co-develop the compound, share the cost incurred, and co-promote the resulted product in the United States after regulatory approval. Upon Acucela exercising its opt-in right, Otsuka will receive a pre-determined opt-in fee and milestone payments.
In June 2016, Acucela announced that the Company received a written termination notice (the Notice) from Otsuka Pharmaceutical for the co-development and commercialization agreement between the Company and Otsuka Pharmaceutical relating to the Companys product candidate emixustat hydrochloride =and the development and collaboration agreement between the Company and...See full deal structure in Biomedtracker
Additional information available to subscribers only: